Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis

Table 4 Cox model analysis for 66 ESCC patients with locoregional recurrence after matching

Variable	n	Univariate			Multivariate
Variable	n	HR	95%CI	P	HR	95%CI	P
Age (years)
< 65/≥65	42/24	0.736	0.407–1.330	0.310
KPS
70–80/>80	27/39	0.843	0.491–1.447	0.535
Gender
Male/Female	48/18	0.942	0.530–1.674	0.838
Smoking
Yes/No	23/43	1.486	0.857–2.577	0.159
Alcohol consumption
Yes/No	10/56	1.083	0.526–2.233	0.828
Primary tumor location
Upper/Middle and lower thoracic	27/39	1.265	0.733–2.183	0.398
Clinical stage
I + II/III	20/46	1.021	0.561–1.858	0.946	1.541	0.814–2.916	0.184
Surgery in the initial treatment
Yes/No	6/60	2.258	0.942–5.414	0.068
Chemotherapy in the initial treatment
Yes/No	33/33	1.005	0.585–1.729	0.984
Recurrence-free interval (months)
≤12/> 12	29/37	0.739	0.433–1.262	0.268
Pattern of recurrence
LN/PF	9/57	0.277	0.108–0.714	0.008	0.319	0.117–0.869	0.025
Re-RT after recurrence
Yes/No	33/33	0.299	0.167–0.535	< 0.001	0.375	0.201–0.701	0.002
Chemotherapy after recurrence
Yes/No	20/46	0.817	0.456–1.463	0.497
Chemotherapy for both course treatment
Yes/No	10/56	0.621	0.291–1.323	0.217	0.710	0.323–1.562	0.395

Abbreviations: HR Hazard ratio, 95%CI 95% confidence interval, Re-RT Re-irradiation, LN Regional lymph node recurrence alone, PF Primary failure with/without regional lymph node recurrence, KPS Karnofsky performance status

ISSN: 1748-717X